Seydoux, Claire http://orcid.org/0000-0003-3263-086X
Uppugunduri, Chakradhara Rao Satyanarayana http://orcid.org/0000-0002-8928-7049
Medinger, Michael http://orcid.org/0000-0003-0427-7747
Nava, Tiago http://orcid.org/0000-0002-8150-5478
Halter, Joerg http://orcid.org/0000-0003-4304-1956
Heim, Dominik
Chalandon, Yves http://orcid.org/0000-0001-9341-8104
Schanz, Urs
Nair, Gayathri
Cantoni, Nathan http://orcid.org/0000-0001-9002-9015
Passweg, Jakob R.
Ansari, Marc
Funding for this research was provided by:
Baxter International
Les Laboratories Pierre Fabre
Article History
Received: 8 December 2022
Revised: 4 March 2023
Accepted: 17 March 2023
First Online: 21 April 2023
Change Date: 21 December 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41409-023-02166-2
Competing interests
: YC: consulting fees from MSD, Novartis, Incyte, BMS, Pfizer, Abbvie, Roche, Jazz, Gilead, Amgen, Astra-Zeneca, Servier; Travel support from MSD, Roche, Gilead, Amgen, Incyte, Abbvie, Janssen, Astra-Zeneca, Jazz. MA: consulting fees from Jazz pharmaceutical. The other authors disclose no conflict of interest.